Ticker > Company >

Trident Texofab share price

Trident Texofab Ltd.

BSE: 540726 SECTOR: Textile  22.57 K   25   3

337.50
+9.50 (2.90%)
BSE: Today, 04:01 PM

Price Summary

Today's High

₹ 354.5

Today's Low

₹ 330.6

52 Week High

₹ 379

52 Week Low

₹ 99.15

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

506.11 Cr.

Enterprise Value

529.45 Cr.

No. of Shares

1.5 Cr.

P/E

171.27

P/B

9.35

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  36.11

CASH

3.16 Cr.

DEBT

26.5 Cr.

Promoter Holding

32.16 %

EPS (TTM)

₹  1.97

Sales Growth

22.69%

ROE

8.46 %

ROCE

11.43%

Profit Growth

132.46 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year22.69%
3 Year13.14%
5 Year6.06%

Profit Growth

1 Year126.95%
3 Year35.61%
5 Year22.17%

ROE%

1 Year8.46%
3 Year10.38%
5 Year8.42%

ROCE %

1 Year11.43%
3 Year11.61%
5 Year10.72%

Debt/Equity

0.6151

Price to Cash Flow

-36.88

Interest Cover Ratio

1.5505

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2025 32.16 0.00
Jun 2025 32.16 0.00
Mar 2025 35.54 0.00
Dec 2024 46.89 0.00
Sep 2024 57.79 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 36.696277863501% for the Past 3 years.

 Limitations

  • The company has shown a poor revenue growth of 13.1356262628859% for the Past 3 years.
  • Company has negative cash flow from operations of -13.7217.
  • Tax rate is low at 2.5469.
  • The company is trading at a high PE of 171.27.
  • The company is trading at a high EV/EBITDA of 57.6092.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025
Net Sales 26.45 31.69 38.21 28.08 30.64
Total Expenditure 26.72 29.37 36.85 26.01 28.15
Operating Profit -0.28 2.32 1.36 2.06 2.49
Other Income 2.77 -0.26 0.48 0.44 0.39
Interest 1.13 1.38 0.99 0.73 0.96
Depreciation 0.41 0.41 0.41 0.41 0.41
Exceptional Items 0 0.05 -0.05 0 0
Profit Before Tax 0.95 0.33 0.38 1.37 1.51
Tax -0.06 0.02 -0.13 0.35 0.38
Profit After Tax 1 0.3 0.51 1.02 1.13
Adjusted EPS (Rs) 1 0.29 0.38 0.68 0.75

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 49.91 84.29 96.36 99.48 122.06
Total Expenditure 47.03 79.5 90.05 93.22 116.46
Operating Profit 2.88 4.79 6.31 6.27 5.6
Other Income 1.85 0.74 1.9 0.39 3.3
Interest 2.85 2.83 3.71 4.15 4.68
Depreciation 1.02 1.47 1.64 1.65 1.65
Exceptional Items 0.05 0.04 -0.13 0.31 0
Profit Before Tax 0.9 1.27 2.73 1.17 2.58
Tax 0.55 0.29 0.51 0.09 0.07
Net Profit 0.35 0.98 2.22 1.08 2.45
Adjusted EPS (Rs.) 0.35 0.98 2.2 1.07 1.85

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 10.07 10.07 10.07 10.07 13.56
Total Reserves 1.91 2.89 5.11 6.19 33.68
Borrowings 19.19 20.27 18.58 17.74 7.43
Other N/C liabilities 6.38 7.51 6.31 5.62 5.16
Current liabilities 30.23 30.25 37.23 42.28 40.75
Total Liabilities 67.77 70.99 77.31 81.9 100.58
Assets
Net Block 14.21 21.71 23.33 21.74 20.08
Capital WIP 8.89 3.62 0 0 0
Intangible WIP 0 0 0 0 0
Investments 2.48 2.06 3.64 3.74 1.89
Loans & Advances 0.59 0.23 0.22 0.22 0.22
Other N/C Assets 1.6 3.34 3.43 4.1 4.63
Current Assets 40 40.03 46.69 52.1 73.75
Total Assets 67.77 70.99 77.31 81.9 100.58
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 0.9 1.27 2.73 1.17 2.58
Adjustment 2.92 4.64 4.33 5.79 3.82
Changes in Assets & Liabilities -1.63 -4.52 -1.07 -4.13 -19.81
Tax Paid -0.23 0 -0.13 -0.12 -0.3
Operating Cash Flow 1.96 1.39 5.85 2.71 -13.72
Investing Cash Flow -10.19 -4.38 0.37 -0.57 4.5
Financing Cash Flow 8.19 2.99 -6.2 -2.05 12.23
Net Cash Flow -0.05 0 0.02 0.09 3

Corporate Actions

Investors Details

PARTICULARS Sep 2024% Dec 2024% Mar 2025% Jun 2025% Sep 2025%
promoters 57.79 46.89 35.54 32.16 32.16
anjanaben jigishkumar des... 0.48 0.47 0.35 0.32 0.32
chetan chandrakant jariwa... 15.07 14.77 11.19 10.12 10.12
hardik jigishkumar desai 31.01 20.65 15.65 14.15 14.15
hardik jigishkumar desai,... 9.34 9.15 6.93 6.27 6.27
kailashben chandrakant ja... 0.21 0.21 0.16 0.14 0.14
maniya hardik desai 1.17 1.15 0.87 0.79 0.79
rupaben chetanbhai jariwa... 0.19 0.19 0.14 0.13 0.13
trident lifeline limited 0.32 0.31 0.24 0.23 0.23
PARTICULARS Sep 2024% Dec 2024% Mar 2025% Jun 2025% Sep 2025%
investors 42.21 53.11 64.46 67.84 67.84
maulik harendra bandhara - - - - 2.86
shravan harikrishnabhai p... - - 1.35 - 1.22
vishal sanjay surana - - - 1.23 1.50
j d polytex private limit... - - 1.06 0.96 -
national stock exchange o... 1.31 1.28 - 0.88 -
shravan h patel 1.82 1.79 - 1.22 -
savitriben mahendrakumar ... - 2.63 2.03 - -
narshibhai meghjibhai mer... 1.04 1.01 - - -
amit bhupendrabhai halvaw... 1.00 - - - -
dhavl shah 1.43 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CRISIL
Credit CRISIL
Credit CARE
Credit CARE
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY24
Presentation Q4FY21
Presentation Q3FY24
Presentation Q2FY25
Presentation Q2FY22
Presentation Q2FY21

Company News

Trident Texofab - Quaterly Results 13 Aug, 9:16 PM Trident Texofab - Quaterly Results 13 Aug, 9:16 PM Trident Texofab informs about compliance certificate 10 Jul, 6:08 PM Trident Texofab informs about disclosure 1 Apr, 4:50 PM Trident Texofab - Quaterly Results 3 Feb, 5:26 PM Trident Texofab - Quaterly Results 3 Feb, 5:26 PM Trident Texofab - Quaterly Results 3 Feb, 5:26 PM Trident Texofab - Quaterly Results 12 Oct, 3:56 PM Trident Texofab - Quaterly Results 12 Oct, 3:56 PM Trident Texofab - Quaterly Results 12 Oct, 3:56 PM Trident Texofab informs about newspaper publication 5 Sep, 4:47 PM Trident Texofab - Quaterly Results 18 Jul, 3:38 PM Trident Texofab - Quaterly Results 18 Jul, 3:38 PM Trident Texofab - Quaterly Results 18 Jul, 3:38 PM Trident Texofab - Quaterly Results 25 May, 3:10 PM Trident Texofab - Quaterly Results 25 May, 3:10 PM Trident Texofab - Quaterly Results 25 May, 3:10 PM Trident Texofab informs about closure of trading window 30 Mar, 3:28 PM Trident Texofab - Quaterly Results 14 Feb, 6:29 PM Trident Texofab - Quaterly Results 6 Nov, 6:16 PM Trident Texofab - Quaterly Results 6 Nov, 6:16 PM Trident Texofab - Quaterly Results 10 Aug, 6:32 PM Trident Texofab - Quaterly Results 24 Apr, 8:33 PM Trident Texofab - Quaterly Results 24 Apr, 8:33 PM Trident Texofab informs about outcome of board meeting 29 Mar, 2:38 PM Trident Texofab informs about disclosure 25 Mar, 3:32 PM Trident Texofab informs about disclosure 1 Mar, 4:54 PM Trident Texofab informs about disclosure 1 Feb, 5:18 PM Trident Texofab informs about press release 18 Jan, 4:28 PM Trident Texofab - Quaterly Results 16 Jan, 2:11 PM Trident Texofab - Quaterly Results 16 Jan, 2:11 PM Trident Texofab - Quaterly Results 16 Jan, 2:11 PM Trident Texofab informs about press release 7 Dec, 12:34 PM Trident Texofab informs about compliances-certificate 15 Oct, 3:50 PM Trident Texofab informs about board meeting proceedings 11 Oct, 5:04 PM Trident Texofa informs about outcome of board meeting 11 Oct, 5:02 PM Trident Texofab - Quaterly Results 11 Oct, 1:24 PM Trident Texofab - Quaterly Results 11 Oct, 1:24 PM Trident Texofab - Quaterly Results 11 Oct, 1:24 PM Trident Texofab to raise Rs 12 crore through NCDs 19 Sep, 10:30 AM Trident Texofab - Quaterly Results 12 Jul, 4:59 PM Trident Texofab - Quaterly Results 12 Jul, 4:59 PM Trident Texofab - Quaterly Results 12 Jul, 4:59 PM Trident Texofab informs about disclosure 6 Jun, 10:13 AM Trident Texofab - Quaterly Results 21 Apr, 5:54 PM Trident Texofab - Quaterly Results 21 Apr, 5:54 PM Trident Texofab - Quaterly Results 21 Apr, 5:54 PM Trident Texofab - Quaterly Results 19 Jan, 5:54 PM Trident Texofab - Quaterly Results 19 Jan, 5:54 PM Trident Texofab informs about disclosure 29 Dec, 4:50 PM

Trident Texofab Stock Price Analysis and Quick Research Report. Is Trident Texofab an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Trident Texofab. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Trident Texofab has a PE ratio of 178.713264495631 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Trident Texofab has ROA of 2.7512% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Trident Texofab has a Current ratio of 1.8097.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Trident Texofab has a ROE of 8.4618%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Trident Texofab has a Debt to Equity ratio of 0.6151 which means that the company has low proportion of debt in its capital.

  • Sales growth: Trident Texofab has reported revenue growth of 22.69% which is fair in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Trident Texofab for the current financial year is 4.58870585844881%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Trident Texofab is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Trident Texofab is Rs 1.8885. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Trident Texofab in Ticker for free. Also, one can get the intrinsic value of Trident Texofab by using Valuation Calculators, which are available with a Finology ONE subscription. 

Trident Texofab FAQs

Q1. What is Trident Texofab share price today?
Ans: The current share price of Trident Texofab is Rs 337.5.

Q2. What is the market capitalisation of Trident Texofab?
Ans: Trident Texofab has a market capitalisation of Rs 506.107035 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Trident Texofab?
Ans: The PE ratio of Trident Texofab is 178.713264495631 and the P/B ratio of Trident Texofab is 9.34519919811268, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Trident Texofab share?
Ans: The 52-week high share price of Trident Texofab is Rs 379, and the 52-week low share price of Trident Texofab is Rs 99.15.

Q5. Does Trident Texofab pay dividends?
Ans: Currently, Trident Texofab does not pay dividends. Dividend yield of Trident Texofab is around 0%.

Q6. What are the face value and book value of Trident Texofab shares?
Ans: The face value of Trident Texofab shares is Rs 10, while the book value per share of Trident Texofab is around Rs 36.1148. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Trident Texofab?
Ans: Trident Texofab has a total debt of Rs 26.4973 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Trident Texofab?
Ans: The ROE of Trident Texofab is 8.4618% and ROCE of Trident Texofab is 11.4331%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Trident Texofab a good buy for the long term?
Ans: The Trident Texofab long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Trident Texofab undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Trident Texofab appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Trident Texofab’s financials?
Ans: You can review Trident Texofab’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Trident Texofab
X